LONDON, April 10, 2014 /PRNewswire/ --
On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90, up 1.72%, the Dow Jones Industrial Average advanced 1.11%, to finish the day at 16,437.18, and the S&P 500 closed at 1,872.18, up 1.09%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 673.27, up 2.11%, while the same has advanced 0.22% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Cell Therapeutics Inc. (NASDAQ: CTIC), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Celldex Therapeutics Inc. (NASDAQ: CLDX) and Synta Pharmaceuticals Corp. (NASDAQ: SNTA). Free technical research on CTIC, VNDA, CLDX and SNTA can be downloaded upon signing up at:
Shares in Cell Therapeutics Inc. finished the Wednesday's session 6.10% higher at $3.48. A total of 2.09 million shares were traded, which is below its three months average volume of 6.04 million shares. The stock fluctuated between $3.31 and $3.50 during the session. Cell Therapeutics Inc.'s stock has surged 5.14% in the previous three trading sessions, and 82.20% on YTD basis, but the same has declined 7.94% in the last one month. The stock is trading above its 200-day moving average. Cell Therapeutics Inc.'s 50-day moving average of $3.53 is above its 200-day moving average of $2.12. Moreover, shares of the company have a Relative Strength Index (RSI) of 40.43. Sign up today to read free research on CTIC at:
On Wednesday, Vanda Pharmaceuticals Inc.'s stock registered a trading volume of 0.72 million shares, as compared with its three months average volume of 1.31 million shares. The stock ended the day at $15.78, up 5.41% after vacillating between $14.51 and $15.82. Vanda Pharmaceuticals Inc.'s shares have advanced 4.71% in the previous three trading sessions, 3.00% in the last one month and 27.16% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages. Vanda Pharmaceuticals Inc.'s 50-day moving average of $14.90 is above its 200-day moving average of $11.63. Additionally, shares of the company have an RSI of 42.02. Sign up today to read free research on VNDA at:
Celldex Therapeutics Inc.'s stock surged 9.18%, to close the day at $17.00. The stock recorded a trading volume of 2.92 million shares as compared with its three months average volume of 2.36 million shares. The stock oscillated between $15.66 and $17.07 during the trading session. Celldex Therapeutics Inc.'s shares have gained 6.45% in the previous three trading sessions, whereas the same has fallen by 32.97% in the last one month, and 29.78% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Celldex Therapeutics Inc.'s 50-day moving average of $24.27 is above its 200-day moving average of $24.19. Moreover, shares of the company have an RSI of 26.29. Sign up today to read free research on CLDX at:
On Wednesday, Shares in Synta Pharmaceuticals Corp. reported a trading volume of 1.86 million shares, as compared with its three months average volume of 2.60 million shares. The stock ended the day at $4.48, up 10.07% and at an intraday range of $4.10 and $4.49. Synta Pharmaceuticals Corp.'s shares have advanced 10.34% in the previous three trading sessions, while the same has declined 12.67% in the last one month and 14.50% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Synta Pharmaceuticals Corp.'s 200-day moving average of $5.58 is above its 50-day moving average of $5.32. Furthermore, the shares of the company have an RSI of 34.63. Sign up today to read free research on SNTA at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.